Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 4/20 | 0.35 |
| ▸ | MMP9 | P14780 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6768634 | 0.82 | CA12 (0.43) | ALDH1A1LMNASMN1; SMN2NAAAHPGD | |
| SCHEMBL6773324 | 0.78 | HSD11B1 (0.39) | ALDH1A1LMNASMN1; SMN2NAAAHPGD | |
| SCHEMBL6768648 | 0.77 | KCNA5 (0.43) | ALDH1A1LMNASMN1; SMN2NAAAHPGD | |
| SCHEMBL6771937 | 0.77 | ALDH1A1 (0.46) | ALDH1A1LMNASMN1; SMN2HPGDPOLB | |
| SCHEMBL6771966 | 0.74 | ALDH1A1 (0.44) | ALDH1A1LMNASMN1; SMN2NAAAHPGD | |
| SCHEMBL6772860 | 0.72 | MMP2 (0.39) | ALDH1A1HPGDPTGDRMMP2MMP9 | |
| SCHEMBL6772326 | 0.65 | MMP2 (0.50) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL6774604 | 0.62 | NPC1 (0.40) | ALDH1A1LMNASMN1; SMN2NAAAHPGD | |
| SCHEMBL6248367 | 0.59 | CYP1A2 (0.50) | ALDH1A1SMN1; SMN2HPGDPOLBTP53 | |
| SCHEMBL18780384 | 0.58 | MAPT (0.46) | ALDH1A1LMNASMN1; SMN2HPGDMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0861281-B1 | Thermosetting bismaleimide polymer for composite and adhesive applications | CYTEC TECH CORP (US) | 2002-06-05 | — | — | EP | claimed |
| US-6762198-B2 | SUCH AS 2-((4'-METHOXY-(1,1'-BIPHENYL)-4-YL)-SULFONYL)-AMINO-3-(2-PHENOXYMETHYL -(1,3)DIOXAN-2-YL)PROPIONIC ACID | THE PROCTER & GAMBLE COMPANY | 2004-07-13 | — | — | US | disclosed |
| US-20030225074-A1 | Dihetero-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-6566381-B1 | For therapy of arthritis, cancer, cardiovascular disorder, skin disorder, ocular disorder, inflammation and gum disease | THE PROCTER & GAMBLE COMPANY | 2003-05-20 | — | — | US | disclosed |
| EP-1165530-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000051993-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225074-A1 | Dihetero-substituted metalloprotease inhibitors | ADAM9, ADAM17, ADAM8 | ALDH1A1 966/4885LMNA 2052/4885SMN1; SMN2 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.